Maze Therapeutics (MAZE) is scheduled to report Q4 earnings on March 31, 2026. Analysts estimate EPS of $-0.70 and quarterly revenue of N/A.

In the most recent quarter (Q3), Maze Therapeutics reported EPS of $-0.66, beating estimates of $-0.71 by 0.07%. Revenue came in at $0.00, missing the estimate of $2.08M by 1.00%.

Maze Therapeutics has beaten EPS estimates in 2 consecutive quarters.

Over the last 2 quarters, Maze Therapeutics has averaged an EPS surprise of 0.12% and a revenue surprise of 1.00%.